I. Lamrissi‐Garcia

发表

CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

G. Cullot, J. Boutin, J. Toutain, 2019, Nature Communications.

Human cell engraftment after busulfan or irradiation conditioning of NOD/SCID mice.

I. Lamrissi‐Garcia, C. Ged, F. Mazurier, 2006, Haematologica.

Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria.

I. Lamrissi‐Garcia, C. Ged, E. Richard, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Spleen route accelerates engraftment of human hematopoietic stem cells.

J. Boutin, I. Lamrissi‐Garcia, J. Blouin, 2021, Biochemical and biophysical research communications.

A bicistronic SIN‐lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, The journal of gene medicine.

Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, Journal of Molecular Medicine.

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

W. Vainchenker, I. Lamrissi‐Garcia, M. Tulliez, 2008, Blood.

Highly Efficient Lentiviral Gene Transfer in CD34+ and CD34+/38−/lin− Cells from Mobilized Peripheral Blood after Cytokine Prestimulation

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2003, Stem cells.

Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2010, The journal of gene medicine.

Preventing Pluripotent Cell Teratoma in Regenerative Medicine Applied to Hematology Disorders

F. Béliveau, I. Lamrissi‐Garcia, S. Dabernat, 2016, Stem cells translational medicine.

Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2020, Blood.

Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria).

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2019, Biochemical and biophysical research communications.

Study of CCN3 (NOV) and DDR1 in normal melanocytes and vitiligo skin

I. Lamrissi‐Garcia, Alice Bibeyran, M. Cario-André, 2012, Experimental dermatology.

Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

I. Lamrissi‐Garcia, M. Lalanne, C. Ged, 2008, American journal of human genetics.

Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells

G. Cullot, J. Boutin, J. Toutain, 2020, Stem cell reports.

Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells

I. Lamrissi‐Garcia, S. Dabernat, F. Moreau-Gaudry, 2017, Leukemia.

HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.

J. Gribben, I. Lamrissi‐Garcia, F. Mazurier, 2013, Cell stem cell.

CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells

D. Cappellen, G. Cullot, J. Boutin, 2021, Nature Communications.

A clinical‐scale expansion of mobilized CD34+ hematopoietic stem and progenitor cells by use of a new serum‐free medium

I. Lamrissi‐Garcia, J. Reiffers, V. Praloran, 2006, Transfusion.

A knock-in mouse model of congenital erythropoietic porphyria.

P. Dubus, I. Lamrissi‐Garcia, M. Lalanne, 2006, Genomics.

CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

G. Cullot, J. Boutin, J. Toutain, 2019, Nature Communications.